Zacks Research Upgrades Emergent Biosolutions (NYSE:EBS) to Hold

Emergent Biosolutions (NYSE:EBS) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other analysts have also weighed in on EBS. UBS Group reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Emergent Biosolutions in a research report on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, HC Wainwright lowered their price target on shares of Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Emergent Biosolutions Stock Up 2.2%

NYSE EBS opened at $4.55 on Tuesday. Emergent Biosolutions has a twelve month low of $4.36 and a twelve month high of $14.06. The stock has a market cap of $233.29 million, a PE ratio of -1.28 and a beta of 2.35. The firm has a 50-day simple moving average of $7.59 and a 200 day simple moving average of $8.60. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, research analysts forecast that Emergent Biosolutions will post -4.63 EPS for the current year.

Insider Buying and Selling at Emergent Biosolutions

In other news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.00% of the company’s stock.

Institutional Trading of Emergent Biosolutions

A number of large investors have recently bought and sold shares of EBS. Legal & General Group Plc acquired a new position in Emergent Biosolutions during the second quarter worth $31,000. Torren Management LLC bought a new position in shares of Emergent Biosolutions during the fourth quarter valued at $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions in the 4th quarter valued at $45,000. Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at $53,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 4,827 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

Key Emergent Biosolutions News

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $10 price target. The firm projects Emergent will return to profitability in 2027, forecasting fiscal 2027 EPS of $0.28 after an estimated fiscal 2026 loss of $4.63 per share. Longer-term earnings expectations provide a potential recovery catalyst if the company stabilizes operations. HC Wainwright forecast article
• Neutral Sentiment: Management’s Q2 2026 earnings call transcript is now available. Investors are likely examining the call for additional detail on the NARCAN franchise, competitive conditions, pricing, cost controls and the path toward the projected 2027 profitability. Emergent BioSolutions Q2 2026 earnings call transcript
• Negative Sentiment: Emergent disclosed a $191.3 million non-cash impairment charge against its NARCAN franchise. The write-down was attributed to increased competition and pricing pressure in the naloxone market, raising concerns about the franchise’s future revenue and profitability. Levi and Korsinsky investor investigation notice
• Negative Sentiment: A law firm announced an investor investigation following shareholder losses. Although the announcement does not establish wrongdoing, the investigation adds legal and reputational risk and may increase volatility.
• Negative Sentiment: Near-term earnings forecasts remain weak. HC Wainwright expects losses of $0.75 per share in Q3 2026 and $0.64 in Q4 2026, reinforcing concerns that the impairment and NARCAN market pressures will continue affecting results.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.